Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Randox

- PMLiVE

Life sciences leaders warn against ‘unworkable’ changes to UK medicines scheme

The scheme could impact UK life sciences and NHS patient access to medicines

- PMLiVE

Health and Social Care Committee report on vaccination calls for urgent action in the UK

In England, coverage for childhood immunisations was below target in 2021 and 2022

- PMLiVE

UK life sciences sector sees substantial drop in international investment

The estimated value of inward foreign direct investment fell from £1.9bn in 2021 to £1bn in 2022

- PMLiVE

Shionogi to acquire Qpex Biopharma for approximately $140m

The deal signifies a notable expansion to the Japanese drugmaker’s antimicrobial pipeline

- PMLiVE

Shionogi’s cefiderocol shows efficacy against difficult-to-treat bacterial infections

Antimicrobial resistance has been declared as one of the top ten threats to global health

- PMLiVE

MHRA to introduce new UK clinical trials framework

The changes will aim to make it easier to gain approval and to run clinical trials in the UK

- PMLiVE

ABPI welcomes new NHS research guidance for integrated care systems

Included in the proposals are calls for a fixed rebate rate of 6.88% on all eligible NHS medicine sales to be paid by the industry

- PMLiVE

Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches

This is only the eighth time in the past 40 years that ABPI has issued such a significant sanction

- PMLiVE

European MPs call for urgent action against antimicrobial resistance

It is estimated that AMR could lead to as many as ten million deaths each year by 2050

- PMLiVE

Shionogi signs licence agreement with MPP for COVID-19 oral antiviral treatment

The agreement aims to increase access to ensitrelvir in low- and middle-income countries

- PMLiVE

Shionogi’s antiviral COVID-19 treatment meets phase 3 primary endpoint

Ensitrelvir reduced the time taken to resolve five key symptoms

- PMLiVE

Shionogi, GARDP and CHAI team up to increase antibiotic access worldwide

The licence and collaboration agreements will provide 135 countries access to cefiderocol

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links